Voisin Consulting Life Sciences publication icon

Cell and Gene Therapies: Addressing the Challenges in Translation

Post thumbnail Cell and Gene Therapies: Addressing the Challenges in Translation

Advanced therapy medicinal products (ATMPs), i.e., cell and gene therapy products, is a rapidly evolving field of therapeutic development. A significant proportion of the products are being developed by academia or small/medium-sized enterprises (SMEs).

The many challenges in translation posed by this class of products include aspects covering: manufacturing, non-clinical development plan as relevant to clinical trial, marketing authorization, and reimbursement. In this context, the term translation refers to the relevance of non-clinical data in relation to how it impacts on appropriate and efficient clinical development. In order to successfully overcome these challenges, a clear
understanding of the requirements and expectations of all the stakeholders is critical. This article aims to cover the potential challenges related to such translation and suggested approaches to find solutions based on experience and learnings from the perspective of European Union.

Cecile F. Rousseau, Director, Romaldas MaciulaitisDariusz SladowskiGopalan Narayanan, VP Disruptive Biologics


Published on: May, 2018


Voisin Consulting Life Sciences download icon

Download the full publication now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    publication by

    Cécile Rousseau
    Cécile F. Rousseau, PhD
    Senior Director, Nonclinical
    With 10+ years in nonclinical and translational research and histotechnology, Dr. Cécile F. Rousseau has considerable expertise in medical devices,…
    View profile